Back to library
LongevitySubcutaneous
FOXO4-DRI
Also known as: FOXO4-D-Retro-Inverso · Senolytic Peptide
D-retro-inverso peptide derived from the FOXO4-p53 interaction domain. Disrupts the FOXO4-p53 complex in senescent cells, releasing p53 to induce apoptosis specifically in cells that have stalled in senescence — leaving healthy cells unaffected in murine studies.
At a glance
- Half-life
- 6 hours
- Common route
- Subcutaneous
- Typical dose range
- 1,000–5,000mcg
- Stability (reconstituted)
- 14days refrigerated
Best timing
Cycled — common research protocol is 3 doses over 1 week, then repeated quarterly. No established human dosing.
Contraindications
- Pregnancy
- Active cancer (p53 activation in tumor context is unpredictable)
- No human clinical trials — pre-clinical only
Watch symptoms
- No characterized human side effect profile
- Theoretical 'senescence flare' — transient inflammation as senescent cells clear
- Injection site reactions
- Long-term consequences of senolytic clearance in humans unknown
Citations